Generics triumph in anti-inflammatory patent battle


Pfizer has settled a long-running patent dispute with generics heavyweights Teva and Actavis, which will allow them to produce generic versions of Pfizer's non-steroidal anti-inflammatory drug Celebrex (celecoxib) in the US.

The deals allow Teva and Actavis to launch their generic versions of the selective COX-2 inhibitor in December 2014, or potentially earlier under certain circumstances. Both companies have filed for approval with the US Food and Drug Administration, and will jostle for ‘first to file’ priority, which under US law will grant 180 days’ exclusivity for generic versions from the successful company.

The settlement follows a prolonged back-and-forth skirmish, with a US court invalidating one of Pfizer’s patents, only for it to be reinstated on appeal. But a successful challenge from Actavis knocked it back down again. By settling the dispute, Pfizer has bought itself seven months extra exclusivity, while allowing the generics companies to enter the market 11 months earlier than they would have done had the patent stood.


Related Content

Generics giants jostle over pain drug

4 June 2014 Business

news image

Mylan and Actavis contest Teva’s generic celecoxib exclusivity

Megamerger brings Actavis into R&D race

25 February 2014 Business

news image

$25bn Forest Labs takeover will see generics giant take on patented products

Most Read

Schott's glass

29 April 2015 Classic Kit

news image

Life through a lens

First pictures of hydrogen bonds unveiled

26 September 2013 Research

news image

Observation of intermolecular interactions in quinolines could help to settle the nature of this kind of bonding

Most Commented

Science for life: a manual for better living

1 May 2015 Review

news image

Looking beyond the hype

An unfortunate oversight

27 April 2015 Critical Point

news image

The US Toxic Substances Control Act is in dire need of reform. That demands compromises, says Mark Peplow